Search Results

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, announced the award of a contract from HDT Bio for the purpose of rapid, next-generation vaccine development under a ‘Project NextGen: Enabler’ award to HDT Bio.

HDT Bio Corp. today announced that it has partnered with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, under Project NextGen’s Enabler’s program.

HDT Bio Corp. prevent infectious diseases and cancer, today announced its participation at the World Vaccine Congress West Coast 2023 in Santa Clara, California, from November 27 through 30, 2023.

HDT Bio Corp., a clinical-stage private company developing advanced RNA products to treat and prevent infectious diseases and cancer, today announced that Dr. Steven Reed, Chief Executive Officer of HDT Bio, will present at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting in San Diego, California, on November 3.

HDT Bio Corp. announced that it has received a $1 million award from the BLUE KNIGHT™ Resident QuickFire Challenge.

HDT Bio Corp. today announced the publication of preclinical data demonstrating that the company’s AMPLIFY vaccine platform holds a more favorable safety profile and increased durability and localization compared to repRNA vaccines delivered by lipid nanoparticles (LNPs), similar to those used to deliver currently-available RNA vaccines for COVID-19.

Passage Bio’s workforce reduction could affect about 32 people, leaving the company with 26 employees as it continues evaluating a treatment for frontotemporal dementia with granulin mutations.

HDT Bio Corp. today announced the peer-reviewed publication of preclinical data demonstrating that its self-amplifying replicon mRNA (repRNA) vaccines, delivered via HDT Bio’s proprietary LION nanoparticle formulation, provide robust maternal and neonatal immunogenicity against two pathogens with high mother-to-child transmission risk: HIV-1 and Zika virus (ZIKV).